Image
Icon

Directory

IconAssociations and Institutes
IconBBBEE Consulting and Verification Agencies
IconCompare Medical Scheme Benefits
IconConsumer Protection
IconCorporate Governance
IconCredit Bureaus
IconEmergency Medical Rescue
IconExpatriate Cover
IconHealthcare Consultants
IconMedical Aid Brokers
IconMedical Aid Schemes
IconMedical Schemes Trustees Liability Insurance
IconMedical Service Providers
IconOmbud
IconOnline Quotes
IconPublications
IconRegulatory Authorities
IconWellness Programs
Image
  Subscribe To »

Novartis – pioneering the way forward in the treatment of NCDs

Published

2017

Mon

31

Jul

  • 4 out of top 10 leading causes of death in SA are due to NCDs
  • 17 biosimilar medicines from Novartis in the pipeline to fight NCDs in SA
Johannesburg: In South Africa, two out of every five deaths can be attributed to non-communicable diseases (NCDs) and injuries; 40 percent of deaths among men, and 29 percent among women are premature and before the age of 60. Over 40 percent of the population suffers from high blood pressure, and over ten percent has high blood glucose, increasing the risk for diabetes.
 
The NCDs causing the highest number of deaths in SA are cardiovascular diseases (18%), cancer (7%), respiratory diseases (4%), diabetes (2%) and other NCDs such as asthma and cataracts (9%).
 
While NCDs are the leading causes of death globally, SA is still battling the HIV/AIDS and TB epidemics, which top the mortality lists. But NCDs are fast catching up and more and more South Africans are becoming ill and dying from these diseases. NCDs make up four of the top 10 causes of death in South Africa – and these numbers are on the rise, according to Statistics South Africa.
 
However, it’s not all doom and gloom as much progress has been made in this area. In an effort to overcome the plight of NCDs in South Africa, pharmaceutical company Novartis, has been one of the pioneers in the area of NCDs through its wide portfolio of biologic and biosimilar treatments and the company continually conducts research to discover other breakthrough medicines in this regard.
 
Three things that can help combat the plight of NCDs include: the reduction of underlying risk factors (tobacco use, physical inactivity, unhealthy diets, and harmful use of alcohol), early detection, and timely treatments.
 
It is in the last of the three, namely timely treatments, that the use of biologics and biosimilars can make such a huge difference to South Africans.
 
The role of biologics and biosimilar treatments
 
Biologics are made using human or animal proteins – a complicated and lengthy process. They do something which normal medications cannot do, namely block specific interactions in the immune system, and so are able to fight diseases in a new and effective manner.
 
Biologics are particularly effective in treating inflammation, auto-immune diseases, cancer, cardiovascular diseases and metabolic conditions; all of which are on the rise in South Africa.
 
A substantial amount of time and research goes into developing biologics and there are strict guidelines to which these medicines must adhere, making their timeframe for entry to market that much longer. However, biosimilars, which are similar to existing biological medicines, are already approved for use, and have specifically been developed to make quick and affordable access to treatments by more South Africans a reality.
 
Novartis was the first to develop and launch biosimilars in every major region of the world.
 
There are currently eleven biosimilar medicines in the pipeline from Novartis, with six more to follow in 2018.
 
“Sandoz, Novartis’ generic and biosimilar pharmaceutical division, has decades of experience in pharmaceutical biotechnology and is recognised as a worldwide pioneer and leader in the production of biosimilars, which are safe, effective, high quality and affordable versions of existing biological medicines,” says Dr Thomas Kowallik, CEO and Country President of Novartis SA.
 
Part of the SA government’s plan to combat the rising number of deaths from NCDs lies in the cost-effective management (by treatment) of high-risk individuals, and it is here that the biosimilars made available by Novartis can save a huge number of lives in SA.
 
Source: Bespoke Strategic Communications
 
« Back to previous page Print this page » |
 

Breaking News »

South African Constitutional Court rethinking the “once-and-for-all rule”

By Kristen Wagner, Candidate Attorney and Deon Francis, Partner, Clyde & Co www. clydeco. com In the recent decision of MEC, Health and Social Development, Gauteng v DZ [2017] ZACC 37, the Constitutional ...
Read More »

  

MSD Announces Local Regulatory Approval of New Oncology Drug

Johannesburg, South Africa: MSD known as Merck & Co. , Inc. , (NYSE: MRK) in the United States and Canada, welcomes the regulatory approval of their new immuno-oncology drug, Pembrolizumab. In recognising the ...
Read More »

  

National Diabetes Month and World Diabetes day

Diabetes and depression can go hand in hand World diabetes day is celebrated annually around the world, on 14 November and Diabetes month during November. Dealing with the news that you have diabetes and have ...
Read More »

  

Novartis urges women to reduce their diabetes risk

Johannesburg: Ahead of World Diabetes Day on 14 November, Novartis South Africa has called on women to make themselves aware of diabetes risk factors and take steps to improve their health and that of their families ...
Read More »

 

More News »

Image

Investment »

Image

Life »

Image

Retirement »

Image

Short-term »

Advertise Here
Image
Advertise Here

From The Glossary »

Icon

Insurable Interest:

A long-standing principle enshrined in life insurance law is that the person taking out or effecting a life insurance policy should have an "insurable interest" in the person whose life is to be insured. This principle has a long history and was first introduced in England to counter the practice of gambling - mainly by taking out policies on the lives of prominent persons such as a prime minister, with whom the policyholder had no connection whatever ...
More Definitions »

 
 
By using this website you agree to the Terms of Use.
Copyright © Stoker Risk & ICT (Pty) Ltd 2004 - 2017.
All Rights Reserved.
Icon

Advertise

  Icon

eZine

  Icon

Contact IG

Icon

Media Pack

  Icon

RSS Feeds